Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPRANO: SBRT Alone or Followed by Niraparib in Ovarian Cancer
NCT05990192Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Progression-Free Survival at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05990192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990192.